CArdiofocus
Putting PVI control in a whole new light
At CardioFocus, we specialize in providing electrophysiologists with innovative and effective tools that bring new levels of precision and control to the treatment of atrial fibrillation. We are passionate about focusing on the science of laser and pulsed field ablation, balancing the critical factors that lead to durable lesions and successful procedures. We strive to provide world class patient care by providing tailor-made solutions to optimize energy delivery across all of our product portfolios.
CardioFocus is headquartered in Marlborough, MA. The HeartLight X3 catheter, endoscope, sheath, console and balloon fill media as well as the Centauri generator are all manufactured in the USA.
News
May 14, 2024
CardioFocus to Present Data Supporting Next Generation Pulsed Field Ablation Systems at Heart Rhythm 2024
January 11, 2024
CardioFocus Acquires Electrophysiology Division of Galvanize Therapeutics
July 19, 2022
CardioFocus Announces Pulsed Field Ablation Milestones
September 14, 2021
CardioFocus Announces Agreement to Acquire Intellectual Property
August 12, 2021
CardioFocus to Participate at the 6th Annual Needham Virtual Med Tech & Diagnostics 1×1 Conference
July 19, 2021
CardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021
June 29, 2021
CardioFocus Appoints Stephan Ogilvie as Chief Financial Officer
June 25, 2021
Cardiofocus® Receives Regulatory Approval to Market HeartLight X3 System in Japan
June 4, 2021
CardioFocus Announces Agreement with China Grand Pharmaceutical to Bring HeartLight X3 System to China
March 16, 2021
CardioFocus® Invited To Participate At The Oppenheimer 31st Annual Healthcare Conference
February 25, 2021
CardioFocus® Announces The Publication Of HeartLight X3 Pivotal Study Data
February 2, 2021
CardioFocus® Announces Expanded Partnership With Japan Lifeline
January 12, 2021
CardioFocus® Invited To Participate In 23rd Annual ICR Conference And Needham Virtual Growth Conference
January 11, 2021
CardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And Portugal
December 15, 2020
CardioFocus® Announces 10,000 Patients Treated Worldwide
June 16, 2020
CardioFocus® Announces Initial Commercial Procedures Following US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation
February 4, 2020
CardioFocus® Announces US FDA PMA Supplement Submission for the Breakthrough HeartLight® X3 Endoscopic Ablation System
January 22, 2020
CardioFocus® Names Burke T. Barrett as Chief Executive Officer
January 12, 2020
CardioFocus® Announces US FDA Approval of HeartLight® X3 System for the Treatment of Atrial Fibrillation
October 29, 2019
CardioFocus® Treats First Patients with HeartLight® Endoscopic Ablation System in France
June 18, 2019
CardioFocus® Launches 100th HeartLight® Center Worldwide
May 28, 2019
CardioFocus® Secures $55 Million In Financing
May 10, 2019
CardioFocus® Announces Impressive Results From Pivotal Confirmatory Study With The Breakthrough HeartLight® X3 System
March 25, 2019
CardioFocus® Announces European CE Mark Approval Of Breakthrough HeartLight® X3 System For The Treatment Of Atrial Fibrillation
March 5, 2019
CardioFocus® Initiates Persistent Atrial Fibrillation Study With The Breakthrough HeartLight® X3 System
July 11, 2018
CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan
May 14, 2018
CardioFocus® Announces Successful Live Case Featuring HeartLight® X3 System
May 7, 2018
CardioFocus® FDA Approval Of The Next-Generation HeartLight® Excalibur Balloon™ Designed For The Treatment Of Paroxysmal Atrial Fibrillation*
February 26, 2018
CardioFocus® Announces Initiation of HeartLight® X3 Clinical Evaluation
January 9, 2018
CardioFocus® Announces Expanded Partnership With Japan Lifeline
November 29, 2017
CardioFocus® Completes Successful Controlled U.S. Commercial Launch Of The HeartLight® System
September 27, 2017
CardioFocus® Announces European CE Mark Approval Of The Next-Generation HeartLight® Excalibur Balloon™ Designed For The Treatment Of Atrial Fibrillation
July 31, 2017
CardioFocus® Receives Approval For HeartLight® Endoscopic Ablation System From The Japanese Ministry Of Health, Labour And Welfare
June 29, 2017
CardioFocus® Announces Initiation Of Three Major Studies Featuring The HeartLight® System For The Treatment Of Atrial Fibrillation
June 6, 2017
Na Homolce Hospital Treats 500th Patient Using HeartLight Endoscopic Ablation System
March 29, 2017
CardioFocus® Completes $20 Million Equity Financing
January 19, 2017
CardioFocus® Announces Initial Clinical Evaluation of Next-Generation HeartLight® Excalibur Balloon™ Designed For the Treatment of Atrial Fibrillation
October 27, 2016
CardioFocus Strengthens Commercial Team with Appointments of Chief Commercial Officer and Vice President of U.S. Sales
September 27, 2016
CardioFocus Begins U.S. Commercialization of HeartLight® System for Paroxysmal Atrial Fibrillation with First Procedure at Mount Sinai
April 4, 2016
CardioFocus’ HeartLight® System Granted FDA Approval for Treatment of Atrial Fibrillation (AF)
September 15, 2015
CardioFocus’ HeartLight® PMA for the Treatment of Atrial Fibrillation Filed and Accepted for Review by the FDA
May 15, 2015
CardioFocus’ HeartLight® U.S. Pivotal Results Presented at Late-Breaking Clinical Trial Session at Heart Rhythm 2015
January 5, 2015
CardioFocus partners with Japan Lifeline for distribution of the HeartLight Laser Balloon to treat Atrial Fibrillation
View All